<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.92010</article-id><article-id pub-id-type="publisher-id">WJCR-29627</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190200000_21950593.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  伊马替尼和尼洛替尼治疗慢性粒细胞白血病的疗效比较研究
  Observation of Imatinib and Nilotinib in the Treatment of Chronic Myeloid Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>宇瑶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>洁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>瑞仓</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>晓霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>洪岭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>河北省人民医院血液科，河北 石家庄</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>03</month><year>2019</year></pub-date><volume>09</volume><issue>02</issue><fpage>69</fpage><lpage>74</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨选择不同TKIs药物治疗慢性粒细胞白血病的疗效。方法：选取接受一代TKIs-伊马替尼(IM)或二代TKIs-尼洛替尼(NI)治疗的CML患者，检测不同时间节点外周血的BCR-ABL融合基因mRNA表达水平，评价治疗效果。结果：有效性评估：以MMR (BCR-ABLIS ≤ 0.1%)作为评估患者预后的指标，A、B、C、D组3个月的MMR率分别为7.3%、0%、27.6%、4.8%；6个月的MMR率分别为21.8%、6.7%、48.3%、19.0%；12个月MMR率29.6%、6.7%、85.7%、42.8%；18个月MMR率分别为38.8%、7.1%、78.9%、42.8%；24个月MMR率分别为44.9%、14.3%、89.5%、42.8%。结论：伊马替尼治疗新诊断CML患者的疗效优于非初治患者。与伊马替尼相比，尼洛替尼能使患者达到更早更深的分子缓解。尼洛替尼对于伊马替尼耐药或不耐受患者有较好的疗效。
    Objective: To investigate the difference of efficacy between imatinib and nilotinib in patients with chronic myeloid leukemia. Methods: A total of 120 patients treated with TKIs were enrolled in this study. The mRNA expression levels of BCR-ABL fusion gene in blood were detected in different times. The clinical data and follow-up results were analysed retrospectively to evaluate the ther-apeutic effect. Results: Evaluation of efficacy: The rates of major molecular response (MMR) at 3 months in four groups were 7.3%, 0%, 27.6% and 4.8%. The rates of MMR at 6 months in four groups were 21.8%, 6.7%, 48.3% and 19.0%. MMR rates at 12 months in four groups were 29.6%, 6.7%, 85.7% and 42.8%. MMR rates at 18 months in four groups were 38.8%, 7.1%, 78.9%, 42.8%. MMR rates at 24 months in four groups were 44.9%, 14.3%, 89.5% and 42.8%. Conclusion: The ef-ficacy of imatinib in the treatment of newly diagnosed CML patients was better than that of patients who were diagnosed for more than 6 months. Nilotinib induced strikingly higher and faster major molecular response, with a statistically significant difference compared with imatinib. Nilotinib was confirmed to be effective for patients with imatinib-resistant or intolerant. 
  
 
</p></abstract><kwd-group><kwd>慢性粒细胞白血病，酪氨酸激酶抑制剂，伊马替尼，尼洛替尼，疗效, Chronic Myeloid Leukemia</kwd><kwd> Tyrosine Kinase Inhibitors</kwd><kwd> Imatinib</kwd><kwd> Nilotinib</kwd><kwd> Efficacy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>伊马替尼和尼洛替尼治疗慢性粒细胞白血病的疗效比较研究<sup> </sup></title><p>王宇瑶，杨洁，李杰，王瑞仓，袁军，李燕，张晓霞，郝洪岭<sup>*</sup></p><p>河北省人民医院血液科，河北 石家庄</p><disp-formula id="hanspub.29627-formula12"><graphic xlink:href="//html.hanspub.org/file/2-2150174x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年3月17日；录用日期：2019年4月2日；发布日期：2019年4月9日</p><disp-formula id="hanspub.29627-formula13"><graphic xlink:href="//html.hanspub.org/file/2-2150174x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨选择不同TKIs药物治疗慢性粒细胞白血病的疗效。方法：选取接受一代TKIs-伊马替尼(IM)或二代TKIs-尼洛替尼(NI)治疗的CML患者，检测不同时间节点外周血的BCR-ABL融合基因mRNA表达水平，评价治疗效果。结果：有效性评估：以MMR (BCR-ABL<sup>IS</sup> ≤ 0.1%)作为评估患者预后的指标，A、B、C、D组3个月的MMR率分别为7.3%、0%、27.6%、4.8%；6个月的MMR率分别为21.8%、6.7%、48.3%、19.0%；12个月MMR率29.6%、6.7%、85.7%、42.8%；18个月MMR率分别为38.8%、7.1%、78.9%、42.8%；24个月MMR率分别为44.9%、14.3%、89.5%、42.8%。结论：伊马替尼治疗新诊断CML患者的疗效优于非初治患者。与伊马替尼相比，尼洛替尼能使患者达到更早更深的分子缓解。尼洛替尼对于伊马替尼耐药或不耐受患者有较好的疗效。</p><p>关键词 :慢性粒细胞白血病，酪氨酸激酶抑制剂，伊马替尼，尼洛替尼，疗效</p><disp-formula id="hanspub.29627-formula14"><graphic xlink:href="//html.hanspub.org/file/2-2150174x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2150174x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2150174x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>慢性粒细胞白血病(chronic myelocytic leukemia, CML)是一种发生在多能造血干细胞上的恶性骨髓增殖性肿瘤。患者出现特征性的染色体易位t(9; 22) (q34; q11) (即Ph染色体)，形成BCR-ABL融合基因，表达异常BCR-ABL蛋白，持续激活酪氨酸激酶，最终导致CML发生。分子靶向药物酪氨酸激酶抑制剂(TKIs)能靶向作用于具有异常酪氨酸蛋白激酶(TPK)活性的BCR-ABL蛋白，可以极大地改善治疗效果，延长生存，已成为CML患者的标准治疗。第一代TKIs-伊马替尼(Imatinib, IM)作为一线药物在治疗CML上取得了巨大的成功，但是临床治疗显示，15%~20%的CML-CP患者对伊马替尼耐药或不耐受。第二代TKIs-尼洛替尼(Nilotinib, NI)是一种新型高亲和力的以氨基嘧啶为基础的ATP竞争性抑制剂，其结构与伊马替尼相似。国外相关研究报道表明，第二代TKI较第一代TKI能够更快地达到分子学缓解(MR) [<xref ref-type="bibr" rid="hanspub.29627-ref1">1</xref>] 。本研究拟通过监测应用不同TKIs药物治疗的CML患者BCR-ABL融合基因水平的变化，探讨两种不同TKIs治疗的有效性，为临床用药选择提供依据。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 研究对象及分组</title><p>自2014年1月至2015年10月期间河北省人民医院血液科收治的接受TKIs治疗的CML患者共120例，其中接受伊马替尼治疗的患者共70例，分为A组(初治组，确诊6个月内接受IM治疗) 55例和B组(非初治组，既往接受羟基脲或干扰素治疗，确诊6个月以上) 15例。接受尼洛替尼治疗的患者共50例，分为C组(一线NI治疗) 29例，D组(IM治疗失败，二线NI治疗) 21例。所有患者根据sokal评分进行危险度分层，诊断和分期标准符合文献 [<xref ref-type="bibr" rid="hanspub.29627-ref2">2</xref>] 。各组患者临床资料见表1。</p><p>本研究通过医院伦理委员会批准。</p></sec><sec id="s4_2"><title>2.2. 研究方法</title><p>A组、B组共70例患者接受伊马替尼(Imatinib，瑞士Novartis Pharma Schweiz AG，商品名格列卫)治疗，IM 400 mg qd，于进餐时服药。C组、D组共50例患者接受尼洛替尼(Nilotinib，瑞士Novartis Pharma Schweiz AG，商品名达希纳)治疗，NI 300~400 mg bid，服药间隔约12 h，两餐间服药。治疗过程中密切监测血象，若出现严重血液学不良反应，需酌情予以药物减量或暂停用药，并积极采取对症处理措施。</p></sec><sec id="s4_3"><title>2.3. 有效性评估</title><p>每3个月进行一次外周血定量聚合酶链反应(QT-PCR)检测BCR-ABL转录本水平(国际标准化)，直至获得稳定的主要分子学反应(MMR)后可3-6个月一次。评估指标包括3个月达到疗效满意(BCR-ABL<sup>IS</sup> ≤ 10%)的患者比率、6个月达到疗效满意(BCR-ABL<sup>IS</sup> ≤ 1%)的患者比率以及主要分子学反应(MMR, BCR-ABL<sup>IS</sup> ≤ 0.1%)、无进展生存(PFS)和总生存(OS)。治疗反应评价标准参照《中国慢性髓性白血病诊断与治疗指南(2016年版)》。</p></sec><sec id="s4_4"><title>2.4. 统计学方法</title><p>采用SPSS 21.0统计软件完成所有统计学分析。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>以MMR(BCR-ABL<sup>IS</sup> ≤ 0.1%)作为评估患者预后的重要指标，A、B、C、D组3个月、6个月、12个月、18个月、24个月达到MMR的百分率见表2。A组内低危患者和中/高危患者各时间节点达到MMR的百分率见表3，C组内低危患者和中/高危患者各时间节点达到MMR的百分率见表4。</p><p>伊马替尼治疗新诊断CML患者和尼洛替尼一线治疗CML患者的疗效比较：A、C组3个月、6个月、12个月、18个月、24个月MMR率比较，P1 = 0.011，P2 = 0.007，P3 = 0.007，P4 = 0.003，P5 = 0.001，差异均具有统计学意义。</p><p>伊马替尼治疗新诊断CML患者与非初治患者的疗效比较：A、B组3个月、6个月、12个月、18个月、24个月MMR率比较，P1 = 0.282，P2 = 0.181，P3 = 0.068，差异均无统计学意义，P4 = 0.025，P5 = 0.038，差异具有统计学意义。</p><p>尼洛替尼对于一线治疗患者和伊马替尼耐药或不耐受患者的疗效比较：C、D组3个月、6个月、12个月、18个月、24个月MMR率比较，P1 = 0.038，P2 = 0.034，P3 = 0.002，P4 = 0.033，P5 = 0.004，差异均具有统计学意义。</p><p>对不同危险度分层的一线TKIs治疗患者进行疗效比较，A组内低危患者和中/高危患者6个月、12个月、18个月、24个月MMR率比较，差异均具有统计学意义。C组内低危患者和中/高危患者6个月、12个月、18个月、24个月MMR率比较，差异均无统计学意义。</p><p>截止到随访结束，IM治疗组和NI治疗组2年OS率分别为98.6%、100% (差异无统计学意义)，2年PFS率分别为95.7%、94% (差异无统计学意义)。</p><p>在TKIs治疗失败或发生疾病进展的患者中有8例患者进行了BCR-ABL激酶区突变检测，共5例患者检测到突变，IM治疗组4例，其中A组高危患者1例发生F317L突变，B组2例低危患者发生M244V突变，1例中危患者发生M531T突变；NI治疗组1例，为D组中危患者发生M315T突变。其中M531T突变患者更换尼洛替尼继续治疗，M315T患者更换达沙替尼继续治疗。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline characteristics of the patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >Group A (n = 55)</th><th align="center" valign="middle" >Group B (n = 15)</th><th align="center" valign="middle" >Group C (n = 29)</th><th align="center" valign="middle" >Group D (n = 21)</th></tr></thead><tr><td align="center" valign="middle" >Median age (range) (yr)</td><td align="center" valign="middle" >48 (9~79)</td><td align="center" valign="middle" >42 (24~74)</td><td align="center" valign="middle" >43 (18~71)</td><td align="center" valign="middle" >54 (16~74)</td></tr><tr><td align="center" valign="middle" >Sex [no. (%)]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >M</td><td align="center" valign="middle" >39 (71)</td><td align="center" valign="middle" >7 (47)</td><td align="center" valign="middle" >15 (52)</td><td align="center" valign="middle" >14 (67)</td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle" >16 (29)</td><td align="center" valign="middle" >8 (53)</td><td align="center" valign="middle" >14 (48)</td><td align="center" valign="middle" >7 (33)</td></tr><tr><td align="center" valign="middle" >Sokal risk group [no. (%)]</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Low</td><td align="center" valign="middle" >18 (33)</td><td align="center" valign="middle" >7 (47)</td><td align="center" valign="middle" >4 (14)</td><td align="center" valign="middle" >6 (29)</td></tr><tr><td align="center" valign="middle" >Intermediate/High</td><td align="center" valign="middle" >37 (67)</td><td align="center" valign="middle" >8 (53)</td><td align="center" valign="middle" >25 (86)</td><td align="center" valign="middle" >15 (71)</td></tr><tr><td align="center" valign="middle" >Median follow-up time (range) (mon)</td><td align="center" valign="middle" >22.6 (6~24)</td><td align="center" valign="middle" >23.2 (12~24)</td><td align="center" valign="middle" >19.7 (12~24)</td><td align="center" valign="middle" >20 (6~24)</td></tr></tbody></table></table-wrap><p>表1. 入组患者基线特征</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> MMR rates in 4 groups at different time point</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time</th><th align="center" valign="middle" >3 mon</th><th align="center" valign="middle" >6 mon</th><th align="center" valign="middle" >12 mon</th><th align="center" valign="middle" >18 mon</th><th align="center" valign="middle" >24 mon</th></tr></thead><tr><td align="center" valign="middle" >Group A</td><td align="center" valign="middle" >7.3% (4/55)</td><td align="center" valign="middle" >21.8% (12/55)</td><td align="center" valign="middle" >29.6% (16/54)</td><td align="center" valign="middle" >38.8% (19/49)</td><td align="center" valign="middle" >44.9% (22/49)</td></tr><tr><td align="center" valign="middle" >Group B</td><td align="center" valign="middle" >0% (0/15)</td><td align="center" valign="middle" >6.7% (1/15)</td><td align="center" valign="middle" >6.7% (1/15)</td><td align="center" valign="middle" >7.1% (1/14)</td><td align="center" valign="middle" >14.3% (2/14)</td></tr><tr><td align="center" valign="middle" >Group C</td><td align="center" valign="middle" >27.6% (8/29)</td><td align="center" valign="middle" >48.3% (14/29)</td><td align="center" valign="middle" >85.7% (24/28)</td><td align="center" valign="middle" >78.9% (15/19)</td><td align="center" valign="middle" >89.5% (17/19)</td></tr><tr><td align="center" valign="middle" >Group D</td><td align="center" valign="middle" >4.8% (1/21)</td><td align="center" valign="middle" >19.0% (4/21)</td><td align="center" valign="middle" >42.8% (9/21)</td><td align="center" valign="middle" >42.8% (6/14)</td><td align="center" valign="middle" >42.8% (6/14)</td></tr></tbody></table></table-wrap><p>表2. A、B、C、D组各时间节点MMR率</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> MMR rates in Group A at different time points among patients with different Sokal ris</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time</th><th align="center" valign="middle" >6 mon</th><th align="center" valign="middle" >12 mon</th><th align="center" valign="middle" >18 mon</th><th align="center" valign="middle" >24 mon</th></tr></thead><tr><td align="center" valign="middle" >Low risk</td><td align="center" valign="middle" >38.9% (7/18)</td><td align="center" valign="middle" >50% (9/18)</td><td align="center" valign="middle" >62.5% (10/16)</td><td align="center" valign="middle" >75% (12/16)</td></tr><tr><td align="center" valign="middle" >Intermediate/High risk</td><td align="center" valign="middle" >13.5% (5/37)</td><td align="center" valign="middle" >19.4% (7/36)</td><td align="center" valign="middle" >27.3% (9/33)</td><td align="center" valign="middle" >30.3% (10/33)</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >0.003</td></tr></tbody></table></table-wrap><p>表3. A组不同危险度患者各时间节点MMR率</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> MMR rates in Group C at different time points among patients with different Sokal ris</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time</th><th align="center" valign="middle" >6 mon</th><th align="center" valign="middle" >12 mon</th><th align="center" valign="middle" >18 mon</th><th align="center" valign="middle" >24 mon</th></tr></thead><tr><td align="center" valign="middle" >Low risk</td><td align="center" valign="middle" >75% (3/4)</td><td align="center" valign="middle" >100% (4/4)</td><td align="center" valign="middle" >100% (4/4)</td><td align="center" valign="middle" >100% (4/4)</td></tr><tr><td align="center" valign="middle" >Intermediate/High risk</td><td align="center" valign="middle" >44% (11/25)</td><td align="center" valign="middle" >83.3% (20/25)</td><td align="center" valign="middle" >73.3% (11/15)</td><td align="center" valign="middle" >86.7% (13/15)</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.249</td><td align="center" valign="middle" >0.378</td><td align="center" valign="middle" >0.245</td><td align="center" valign="middle" >0.44</td></tr></tbody></table></table-wrap><p>表4. C组不同危险度患者各时间节点MMR率</p></sec><sec id="s6"><title>4. 讨论</title><p>第一代TKIs伊马替尼具有良好的疗效和安全性，已取代造血干细胞移植成为CML的标准治疗方案。但随着IM广泛应用，其耐药性日渐凸显。IM的耐药机制分为BCR-ABL基因依赖耐药和非依赖耐药 [<xref ref-type="bibr" rid="hanspub.29627-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.29627-ref4">4</xref>] ，依赖耐药机制中ABL激酶区突变占50%~80% [<xref ref-type="bibr" rid="hanspub.29627-ref5">5</xref>] 。第二代TKIs尼洛替尼能降低IM耐药的突变细胞的增殖，使大部分IM耐药患者受益。</p><p>Larsond等 [<xref ref-type="bibr" rid="hanspub.29627-ref6">6</xref>] 研究认为，无论初治或接受过其他治疗的CML患者，IM疗效均比较理想。本研究中，IM治疗组3个月和6个月达到疗效满意的患者率为38.6%、40%，表明IM对CML患者有一定的早期反应率。以MMR作为预后评估指标，本研究中IM治疗组12个月、24个月的MMR率分别为24.6%、38.1%，其中A组MMR率达29.6%、44.9%，可见IM治疗CML疗效明显。A组各节点MMR率均高于B组，且18个月、24个月MMR率比较差异有统计学意义，表明IM对于新诊断CML患者的疗效优于非初治患者，尤其对于CML患者长期预后差异明显。通常认为，CML确诊6个月之内尽早选择TKIs治疗可达到更高的缓解率和更好的总生存 [<xref ref-type="bibr" rid="hanspub.29627-ref7">7</xref>] 。</p><p>目前的临床治疗显示，有15%~20%的CML-CP患者对IM耐药或不耐受。第二代TKIs-尼洛替尼是一种新型苯胺嘧啶衍生物，与伊马替尼相比，尼洛替尼具有更好的亲脂性和溶解性，对野生型BCR-ABL非活化构象的亲和性可提高30倍 [<xref ref-type="bibr" rid="hanspub.29627-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.29627-ref9">9</xref>] 。MDACC和GIMEMA两项II期临床研究证明 [<xref ref-type="bibr" rid="hanspub.29627-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.29627-ref11">11</xref>] ，NI一线治疗初诊CML患者具有显著疗效，治疗3个月时MMR率可达52%，提示NI起效快速。本研究中，C组3个月、6个月时治疗达标率及MMR率均高于A组，表明NI一线治疗CML较IM有更早的分子学反应。A组与C组在3个月、6个月、12个月、18个月、24个月的MMR率相比差异显著，这与既往报道的两项第二代TKIs与IM疗效的临床试验 [<xref ref-type="bibr" rid="hanspub.29627-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.29627-ref13">13</xref>] 结果一致，提示NI较IM能更强效抑制BCR-ABL，得到更早更深的分子学缓解。</p><p>研究显示，IM治疗失败后更换二代TKIs，许多CML患者仍可获得长期生存 [<xref ref-type="bibr" rid="hanspub.29627-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.29627-ref15">15</xref>] 。本研究中D组有4例IM不耐受患者，更换NI后均获得MMR。其余17例IM治疗失败的患者更换NI治疗，截止到随访结束，12例患者疗效满意，其中有6例患者已获得MMR。D组12个月、24个月的MMR率均为42.8%。这与一项包含321例IM治疗失败CML患者的临床研究结果相似 [<xref ref-type="bibr" rid="hanspub.29627-ref16">16</xref>] ，提示对于IM耐药或不耐受患者，更换第二代TKIs-NI仍可获得良好的疗效。但由于本研究中D组部分病例随访时间不满24个月，其远期疗效尚有待考证。另外，本研究结果显示，与一线NI治疗组C组相比，D组在3个月、6个月的达标率及各时间节点的MMR率均显著偏低，由此可见，一线NI治疗CML的疗效优于IM更换NI二线治疗。</p><p>D组中有1例患者于NI治疗3~12个月时均达标，至24个月时治疗失败，疾病进展至加速期，检测到BCR-ABL激酶区发生M315T突变，更换相对敏感的达沙替尼治疗，继续随访3个月后BCR-ABLIS定量从16.34%降为8.5%。因此，考虑该例患者疾病进展系因M315T突变所致 [<xref ref-type="bibr" rid="hanspub.29627-ref17">17</xref>] 。</p><p>NI对许多ABL激酶区突变敏感 [<xref ref-type="bibr" rid="hanspub.29627-ref18">18</xref>] 。本研究中，IM治疗组有4例治疗失败患者检测出ABL激酶区突变，其中1例M244V突变和1例M531T突变患者更换尼洛替尼继续治疗，12个月均已达到BCR-ABLIS ≤ 1%。因此对于IM治疗未达到满意疗效的患者，应尽早行BCR-ABL激酶区突变检测，根据检测结果决定是否更换第二代TKIs治疗。</p><p>本研究发现，A组病例中，低危患者和中/高危患者6~24个月的MMR率比较差异均有统计学意义，低危患者达到疗效满意的比例总体高于中/高危患者，表明IM对低危患者疗效更为理想。NI治疗组中，低危组和中/高危组在6个月、12个月、18个月、24个月的MMR率比较无明显差异，提示一线NI治疗对中/高危患者也可达到理想疗效。因此推荐对于中/高危CML患者首选NI治疗。</p><p>截止到随访结束，IM组和NI组2年总生存率(OS)和无进展生存率(PFS)比较无统计学差异，提示NI虽可提高MMR率，但未观察到生存优势。然而，本研究随访时间尚短，需要更大样本、更长时间(5年、10年)的随访观察。</p></sec><sec id="s7"><title>文章引用</title><p>王宇瑶,杨 洁,李 杰,王瑞仓,袁 军,李 燕,张晓霞,郝洪岭. 伊马替尼和尼洛替尼治疗慢性粒细胞白血病的疗效比较研究Observation of Imatinib and Nilotinib in the Treatment of Chronic Myeloid Leukemia[J]. 世界肿瘤研究, 2019, 09(02): 69-74. https://doi.org/10.12677/WJCR.2019.92010</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29627-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rosti, G., Castagnetti, F., Gugliotta, G., et al. (2010) Excellent Outcomes at 3 Years with Nilotinib 800 mg Daily in Early Chronic Phase, Phþchronic Myeloid Leukemia (CML): Results of a Phase 2 Gimema CML WP Clinical Trial. Blood, 116, 8359.</mixed-citation></ref><ref id="hanspub.29627-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张之南, 沈悌. 血液病诊断及疗效标准[M]. 北京: 科学技术出版社, 1998: 1829.</mixed-citation></ref><ref id="hanspub.29627-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ding, K., Su, Y., Pang, L., et al. (2009) Inhibition of Apoptosis by Downregulation of hBexl, a Novel Mechanism, Contributes to the Chemoresistance of BCR/ABL+ Leukemic Cells. Carcinogenesis, 30, 35-42.  
https://doi.org/10.1093/carcin/bgn251</mixed-citation></ref><ref id="hanspub.29627-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">McCormack, P.L. and Keam, S.J. (2011) Dasatinib: A Review of Its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia. Drugs, 71, 1771-1795.  
https://doi.org/10.2165/11207580-000000000-00000</mixed-citation></ref><ref id="hanspub.29627-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Santos, F.P., Kantarjian, H., Quintas-Cardama, A., et al. (2011) Evolution of Therapies for Chronic Myelogenous Leukemia. The Cancer Journal, 17, 465-476. https://doi.org/10.1097/PPO.0b013e31823dec8d</mixed-citation></ref><ref id="hanspub.29627-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Larson, R.A., Druker, B.J., Guilhot, F., et al. (2008) Imatinib Pharma-cokinetics and Its Correlation with Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study. Blood, 111, 4022-4028.  
https://doi.org/10.1182/blood-2007-10-116475</mixed-citation></ref><ref id="hanspub.29627-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李向龙, 朱焕玲, 刘红英, 等. 酪氨酸激酶抑制剂治疗慢性粒细胞白血病的临床疗效分析[J]. 四川大学学报(医学版), 2014, 45(4): 647-651.</mixed-citation></ref><ref id="hanspub.29627-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Weisberg, E., Manley, P.W., Breitenstein, W., et al. (2005) Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl. Cancer Cell, 7, 129-141. https://doi.org/10.1016/j.ccr.2005.01.007</mixed-citation></ref><ref id="hanspub.29627-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">O’Hare, T., Walters, D.K., Stoffregen, E.P., et al. (2005) In Vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research, 65, 4500-4505. https://doi.org/10.1158/0008-5472.CAN-05-0259</mixed-citation></ref><ref id="hanspub.29627-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rosti, G., Palandri, F., Castagnetti, F., et al. (2009) Nilotinib for the Frontline Treatment of Ph(+) Chronic Myeloid Leukemia. Blood, 114, 4933. https://doi.org/10.1182/blood-2009-07-232595</mixed-citation></ref><ref id="hanspub.29627-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Quintas-Cardama, A., Kantarjian, H.M., Rajyalakshmi, L., et al. (2011) Efficacy of Frontline Nilotinib Therapy in Patients(pts) with Newly Diagnosed Philadelphia Chromosome(Ph)-positive Chronic My-eloid Leukemia in Early Chronic Phase (CML-CP). Blood, 118, 454.</mixed-citation></ref><ref id="hanspub.29627-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Larson, R.A., Hochhaus, A., Hughes, T.P., et al. (2012) Nilotinib vs. Imatinib in Patients with Newly Diagnosed Philadephia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up. Leukemia, 26, 2197-2203. https://doi.org/10.1038/leu.2012.134</mixed-citation></ref><ref id="hanspub.29627-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bansal, S. (2014) Is Imatinib Still the Best Choice as First-Line Oral TKI. South Asian Journal of Cancer, 3, 83-86.  
https://doi.org/10.4103/2278-330X.126553</mixed-citation></ref><ref id="hanspub.29627-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Schindler, T., Bornmann, W., Pellicena, P., et al. (2000) Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase. Science, 289, 1938-1942. https://doi.org/10.1126/science.289.5486.1938</mixed-citation></ref><ref id="hanspub.29627-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Shah, N.P., Nicoll, J.M., Nagar, B., et al. (2002) Multiple BCR-ABL Kinase Domain Mutations Confer Polyclonal Resistance to the Tyrosine Kinase Inhibitor Imatinib (STI571) in Chronic Phase and Blast Crisis Chronic Myeloid Leukemia. Cancer Cell, 2, 117-125. https://doi.org/10.1016/S1535-6108(02)00096-X</mixed-citation></ref><ref id="hanspub.29627-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Golemovic, M., Verstovsek, S., Giles, F., et al. (2005) AMN107, AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has in Vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 11, 4941-4947. https://doi.org/10.1158/1078-0432.CCR-04-2601</mixed-citation></ref><ref id="hanspub.29627-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">O’Hare, T., Shakespeare, W.C., Zhu, X., et al. (2009) AP24534, a pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Re-sistance. Cancer Cell, 16, 401-412.  
https://doi.org/10.1016/j.ccr.2009.09.028</mixed-citation></ref><ref id="hanspub.29627-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kantarjian, H.M., Giles, F.J., Kapil, N., et al. (2011) Nilotinib Is Effective in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Resistance or Intolerance: 24-Month Follow-Up Results. Blood, 117, 1141-1145.</mixed-citation></ref></ref-list></back></article>